What Cacit Vitamine D3 treats: main uses and benefits

---

This medication is commonly used for managing combined deficiencies of calcium and Vitamin D and supporting treatment for conditions like osteoporosis. This supplement helps address these deficiencies and may be part of a management plan for osteoporosis. It is considered relevant for supporting these areas of health.

It primarily helps manage conditions characterized by bone thinning, alongside symptoms associated with musculoskeletal discomfort and generalized weakness. The therapeutic goals include supporting stronger bones and providing relevant nutritional support for existing treatments. It is often applied in clinical settings that involve chronic or persistent deficiency states, particularly in older individuals and post-menopausal women.

Quick Fact: Relief for Musculoskeletal Discomfort and Weakness

Official Eligibility Profile for Cacit Vitamine D3

The eligibility for Cacit Vitamine D3 is strictly defined by regulatory documents, focusing on existing physiological conditions and age group.

Contraindications: Must Not Be Used

The medicine is absolutely contraindicated in patients with: hypercalcaemia (high blood calcium), hypercalciuria (high urinary calcium), hypervitaminosis D (excessive Vitamin D levels), nephrolithiasis (kidney stones), or severe renal impairment. Individuals with known hypersensitivity to the active substances or excipients (including those with certain hereditary sugar intolerances) are also prohibited from use.

Age and Conditional Use

Use is indicated for adults and the elderly for correction of combined calcium and Vitamin D deficiency. The product is not intended for use in children or adolescents.

Conditional Use requires special caution and monitoring in patients with impaired renal function (who must be monitored for serum calcium and creatinine), sarcoidosis, or when the patient is immobilized with osteoporosis, due to the increased risk of high calcium levels.

Pregnancy and Lactation

Cacit Vitamine D3 may be used during pregnancy and breastfeeding, but this use is limited. The total daily intake from all sources must not exceed a defined safety threshold of 1500 mg calcium and 600 IU vitamin D, as officially documented overdoses must be avoided.

Cacit Vitamine D3, a combination of calcium and vitamin D3, has documented interactions primarily related to effects on calcium levels and absorption. Certain co-administered medicines may require caution, monitoring, or specific timing adjustments.

Medicines Affecting Calcium Balance

Interacting Product Category	Interaction Mechanism and Effect
Digitalis/Cardiac Glycosides	Increased risk of digitalis toxicity (e.g., cardiac dysrhythmia) due to the combination's impact on calcium concentration. ECG and serum calcium monitoring are necessary.
Thiazide Diuretics	Thiazides decrease calcium excretion, which, when combined with calcium/vitamin D, elevates the risk of hypercalcaemia. Serum calcium and renal function monitoring are warranted, especially in the elderly.
Systemic Corticosteroids	Corticosteroids may reduce the absorption of calcium from the gut, potentially counteracting the supplement's intended effect.

Medicines with Reduced Absorption

Calcium salts can reduce the gastrointestinal absorption and thus the effectiveness of several oral medicines. To mitigate this effect, specific spacing requirements are necessary:

• Tetracycline Antibiotics: Must be taken at least two hours before or four to six hours after the calcium/vitamin D supplement.
• Oral Bisphosphonates, Sodium Fluoride: Must be taken at least three hours before the calcium-containing product.

Other Interactions

Products containing phenytoin or barbiturates can accelerate the metabolism of vitamin D, potentially reducing its therapeutic efficacy. Furthermore, using Cacit Vitamine D3 concurrently with other products containing calcium or vitamin D increases the risk of excessive calcium levels (hypercalcaemia) due to additive effects, necessitating strict medical supervision and frequent monitoring of blood and urine calcium.

How Cacit Vitamine D3 Works

The Vitamin D3 component (cholecalciferol) undergoes two metabolic conversions, first in the liver and then in the kidneys, to yield its biologically active hormone form, calcitriol. Calcitriol acts as an agonist by binding to the intracellular Vitamin D Receptor (VDR), initiating gene transcription in target cells across the small intestine, kidney, and bone. This receptor activation increases the synthesis of proteins required for calcium and phosphate transport, such as calbindin.

This mechanism modulates systemic mineral homeostasis by significantly enhancing the intestinal absorption of both calcium and phosphate from the diet and promoting the renal reabsorption of calcium. This dual action supports the stabilization of circulating mineral concentrations in the plasma. The resulting enhanced systemic availability of these minerals is integral to the final physiological process: the deposition of calcium phosphate crystals into the bone's protein framework, which supports skeletal tissue mineralization.

The administration of Cacit Vitamine D3 is strictly defined by its pharmaceutical form as a fixed-dose combination, mandating oral preparation before ingestion. This medication is exclusively administered through the oral route after preparation as a solution.

Standard Regimen and Frequency

The established regimen for adults, particularly older adults being treated for osteoporosis adjunctively or for combined deficiency, is typically one sachet or effervescent tablet per day. This unit delivers a standard fixed dose of 400 mg of elemental calcium and 800 IU of cholecalciferol (Vitamin D3). Treatment is generally continuous and intended for long-term use for chronic mineral and vitamin support. In the event of a missed dose, a forgotten dose should not be compensated by taking a double dose; the patient must simply resume the established schedule with the next planned dose. The product is not intended for use in the pediatric population.

Required Preparation and Timing

The effervescent format requires mandatory preparation. The entire contents of the sachet or tablet must first be poured into a glass, followed by the addition of a large quantity of water. The resulting oral solution must be consumed immediately once the effervescence has fully ceased. Furthermore, the calcium component introduces a practical timing constraint: patients must maintain a separation of approximately two hours between taking this supplement and other oral medications known to interfere with calcium, such as specific antibiotics or bisphosphonates. This scheduling principle is necessary to prevent interference with the absorption of the concomitant drugs.

Research Evidence / Overview of Studies for Cacit Vitamine D3

---

Evidence for Use in Combined Deficiency States

Research has primarily evaluated this combination of calcium and Vitamin D for adults diagnosed with, or at high risk of, combined nutritional deficiencies. Studies examined how the body processes the combination and whether it leads to measurable changes in the blood. Researchers monitored specific biological markers, such as serum 25-hydroxyvitamin D (25(OH)D) levels and serum calcium levels, which reflect the body's mineral status. Findings described patterns observed in the studies where the combination was associated with changes in these biomarkers. However, the existing studies provide limited information for long-term outcomes that go beyond blood measurements, such as tracking how the biomarker changes influence events like fracture incidence over many years. Data for certain groups, such as children or pregnant individuals, remain insufficient to draw conclusions.

---

Evidence as an Adjunct to Specific Osteoporosis Therapy

An extensive body of research, including large-scale Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses, has evaluated this combination as an adjunct therapy alongside primary treatments for osteoporosis (bone thinning). These trials examined outcomes related to daily functioning, primarily tracking changes in Bone Mineral Density (BMD) and the incidence of hip and non-vertebral fractures. Studies monitored outcomes in older adults, especially postmenopausal women, and often included individuals in care settings. Studies report patterns related to skeletal events, particularly in high-risk populations like institutionalized elderly. However, research highlights that results on reducing the risk of fracture were mixed across studies. In some instances, comparative evidence suggests that when the combination was observed in certain healthier subgroups, limited information exists about its role in influencing fracture risk in those groups.

---

What is Still Uncertain About the Combination

Research highlights several areas where data are still emerging or where the certainty remains low. The evidence quality varies across studies, leading to mixed findings on fracture risk reduction in different patient groups. Specifically, it is not yet clear how much influence the combination has for lower-risk, community-dwelling adults compared to those in institutionalized settings. Furthermore, when this combination is observed alongside primary anti-osteoporosis treatments, the research has difficulty isolating the specific contribution of the calcium and Vitamin D combination itself. This means that comparative evidence is lacking to fully clarify its independent role in all clinical scenarios.

Key Studies & References

1. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation
2. Clinical guideline for the prevention and treatment of osteoporosis 2021 (National Osteoporosis Guideline Group - NOGG)

The official regulatory requirements for storing and disposing of Cacit Vitamine D3 are defined by specific conditions to ensure product integrity and public safety.

Storage Requirements

The medicine must be stored at a temperature not above 25°C (77°F). It is mandatory to keep the product out of the sight and reach of children.

Disposal Instructions

Official labeling explicitly forbids discarding any unused or expired medicine via wastewater or household waste. Disposal must be handled in accordance with local requirements and by consulting a pharmacist on the correct procedures.

Classification	Official Requirement
Temperature Limit	Store not above 25°C
Child Safety	Keep out of sight and reach of children
Disposal Method	Do not throw via household waste or wastewater